Those two companies represent potential partners for our vaccine. |
We are extremely pleased by these results. We believe that they are the first validation of the therapeutic vaccination approach in infectious diseases. These data constitute a significant breakthrough and validate our vaccine technology platform. Our objective is an effective vaccine for pre-cancerous lesions to speed up the fight against cervical cancer which remains a serious health concern globally. |
We are targeting women who are already infected and who have already developed lesions, so our approach is very complementary. |